How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,911 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. A model-based personalized cancer screening strategy for detecting early-stage tumors using blood-borne biomarkers Full Text available with Trip Pro

A model-based personalized cancer screening strategy for detecting early-stage tumors using blood-borne biomarkers An effective cancer blood biomarker screening strategy must distinguish aggressive from nonaggressive tumors at an early, intervenable time. However, for blood-based strategies to be useful, the quantity of biomarker shed into the blood and its relationship to tumor growth or progression must be validated. To study how blood biomarker levels correlate with early-stage viable tumor (...) , biomarker elimination from plasma, and subject-specific tumor growth. We validated the model in a separate set of mice in which subject-specific tumor growth rates were accurately predicted. To illustrate clinical translation of this strategy, we allometrically scaled model parameters from mouse to human and used parameters for PSA shedding and prostate cancer. In this manner, we found that blood biomarker sampling data alone were capable of enabling the detection and discrimination of simulated

2017 Cancer research

202. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model Full Text available with Trip Pro

Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model Background: Transient Receptor Potential Vanilloid 6 (TRPV6), a non-voltage gated calcium channel, is implicated in malignancies and correlates with Gleason scores in prostate cancer and with poor prognosis in breast cancer. Data on the TRPV6 status of ovarian malignancies has not received significant attention. The effect of inhibiting TRPV6 activity (...) on ovarian tumour growth has never been reported. Methods: We quantified TRPV6 mRNA and protein in biopsies of five types of ovarian cancer at different stages and grades by quantitative PCR and immunohistochemistry respectively. We verified the presence of TRPV6 in SKOV-3 cells and xenografts by Western Blotting. NOD/SCID mice bearing xenografted ovarian tumours derived from SKOV-3 were treated daily with TRPV6-antagonistic peptides (SOR-C13 and SOR-C27) at 400, 600 and 800 mg/kg delivered

2018 Journal of Cancer

203. Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy Full Text available with Trip Pro

Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy To assess and validate the incorporation of the multiparametric magnetic resonance imaging (mpMRI) tumour category (mT-category) to the conventional clinical tumour category (cT-category), in order to guide the radiotherapy (RT) treatment decisions in prostate cancer. In addition, to identify the clinical factors associated to the technique reliability. mpMRI was performed (...) . 88.3 %) and HT associated to RT (45.6 vs. 62.4 %). Global accuracy for mpMRI was higher compared to DRE/TRUS (8.9 vs. 71.1 %, p < 0.05). mpMRI reliability was independent of PSA or GS. mpMRI tumor staging significantly modified the RT treatment decisions in all prostate cancer risk groups.

2015 SpringerPlus

204. Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria. Full Text available with Trip Pro

calculated overall survival and cancer-specific survival of subsequent CRC, and more specifically stage IV CRC, using Kaplan-Meier test and adjusted Cox models.A total 550,325 CRC patients were reviewed, of whom 31,663 had history of a prior malignancy. The most commonly reported sites of a prior malignancy were: prostate, breast, urinary bladder, lung, and endometrium. Patients with history of a prior non-leukemic malignancy or history of a prior leukemia were found to have worse overall survival (HR (...)  = 1.165 95%CI = 1.148-1.183, P < 0.001) and (HR = 1.825 95%CI = 1.691-1.970, P < 0.001), respectively. However, CRC patients with history of a prior non-leukemic malignancy showed an improved colorectal cancer-specific survival (HR = .930 95%CI = .909-.952, P < 0.001). Analysis of stage IV CRC patients showed that patients with history of any non-leukemic malignancy did not have a significant change in overall survival. Whereas, patients with a prior leukemia showed a worse overall survival (HR

2019 BMC Cancer

205. Parotid Tumors, Malignant

-year survival for all stages and histologic types is approximately 62%. The overall 5-year survival for recurrent disease is approximately 37%. Because of the risk of recurrence, all patients who have had a histologically proven malignant salivary gland tumor should have lifelong follow-up. A study by Kim et al of 126 patients treated for primary parotid cancer found the following disease-specific survival rates for the various tumor stages (mean follow-up period 29.7 months) [ ] : Stage I (97 (...) Updated: Apr 01, 2019 Author: Bardia Amirlak, MD; Chief Editor: Deepak Narayan, MD, FRCS Share Email Print Feedback Close Sections Sections Malignant Parotid Tumors Introduction and Anatomy The parotid glands are the largest salivary glands in humans and are frequently involved in disease processes. Approximately 25% of parotid masses are nonneoplastic; the remaining 75% are neoplastic. Nonneoplastic causes of parotid enlargement include cysts, , lymphoepithelial lesions associated with AIDS, collagen

2014 eMedicine Surgery

206. Malignant Tumors of the Sinuses

lymphoma (SN-ETNKL). The study, which involved 1054 patients with SN-DLBCL and 328 patients with SN-ETNKL, found that when patients were matched for age, cancer stage, and treatment modality, disease-specific survival rates for SN-DLBCL at 1, 5, and 10 years were 94.4%, 72.8%, and 46.8%, respectively, compared with 77.6%, 38.4%, and 13.9%, respectively, for patients with SN-ETNKL. [ ] Salivary-type neoplasms Pleomorphic adenomas, mucoepidermoid carcinoma, and other salivary gland neoplasms may arise (...) of such tumors can be severe. Treatment of sinonasal malignancies (SNM) is best accomplished through a multidisciplinary team. Optimally, this includes a head and neck oncologic surgeon, reconstructive surgeon, maxillofacial prosthodontist, radiation oncologist, medical oncologist, neuroradiologist, pathologist, and neurosurgeon. Workup As with other head and neck cancers, liver enzymes are usually obtained to assess for distant disease, in addition to a chest radiograph or computed tomography (CT) scan

2014 eMedicine Surgery

207. Malignant Tumors of the Temporal Bone

of the Temporal Bone Updated: Jul 12, 2018 Author: Stephanie A Moody Antonio, MD; Chief Editor: Arlen D Meyers, MD, MBA Share Email Print Feedback Close Sections Sections Malignant Tumors of the Temporal Bone Overview Background Carcinoma of the temporal bone is rare, accounting for fewer than 0.2% of all tumors of the head and neck. Only 200 new cases of temporal bone cancer may be diagnosed each year across the United States. This number includes cancers arising from skin of the pinna that spread (...) to the temporal bone; primary tumors of the external auditory canal (EAC), middle ear, mastoid, or petrous apex; and metastatic lesions to the temporal bone. See the image below. Axial image that shows the spread of temporal bone cancer. Malignancies of the temporal bone arise most commonly from the pinna and lateral concha because these sites are likely to have undergone many years of sun exposure. In these areas, basal cell carcinoma and are most common. [ , ] If neglected, these tumors may spread medially

2014 eMedicine Surgery

208. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update.

of the guideline. This guideline updates a previous version: Rodrigues G, Yao X, Loblaw A, Brundage M, Chin J, Genitourinary Cancer Disease Site Group. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer. Toronto (ON): Cancer Care Ontario (CCO); 2012 Oct 31. 55 p. (Evidence-based series; no. 3-10). [165 references] This guideline meets NGC's 2013 (revised) inclusion criteria. UMLS Concepts ICD9CM (185), (60.5) MSH , , , , , , , , MTH , , , , , , , , PDQ , , , , SNOMEDCT_US (...) brachytherapy; no recommendation can be made for or against using 131 Cs or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. None provided Prostate cancer Treatment Nuclear Medicine Oncology Radiation Oncology Surgery Urology Physicians To provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostate cancer that includes

2017 National Guideline Clearinghouse (partial archive)

209. Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Full Text available with Trip Pro

 = .021), bone metastasis (P = .013), pelvic lymph node metastasis (P = .008), and TNM stage (P = .007). Multivariate Cox regression analyses revealed increased SNHG7 expression was independently associated with a poor prognosis of prostate cancer patients (hazard ratio [HR] = 2.839, 95% confidence interval [CI] = 1.921-8.382, P = .038).This study showed that lncRNA-SNHG7 was overexpressed in prostate cancer tissues, and it might contributes to the development and progression of prostate cancer (...) Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Long non-coding small nucleolar RNA host gene 7 (lncRNA SNHG7) is located on chromosome 9q34.3 in length of 984 bp. SNHG7 has been found to play the role of oncogene in varieties of cancers, and its dysregulation has been found to be associated with carcinogenesis and progression. In the present study, we examined the expression of SNHG7

2020 Medicine

210. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. (Abstract)

from 2005 to 2015. We reviewed each individual's prebiopsy prostate specific antigen (PSA), Gleason score, and clinical stage. We also determined if imaging obtained yielded a false positive, incidental finding, or if metastatic disease occurred within the 6 months following initial diagnosis.There were 414 men, who were classified as low- to intermediate-risk prostate cancer and underwent inappropriate staging imaging of 4,306 men diagnosed with prostate cancer. Of these 414 men, 178 (43%) had (...) Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. According to current National Comprehensive Cancer Network guidelines, routine imagining for staging low-risk prostate cancer is not recommended. However, extensive overuse of guideline-discordant imaging continues to persist. Incidental findings are common on imaging and little is known about the optimal management. Rates of incidental findings vs

2018 Urologic oncology

211. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? (Abstract)

Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? In prostate cancer, disease progression after primary treatment and subsequent androgen deprivation therapy is common. Intensification of systemic treatment is the standard of care. Recently, 68Ga prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging was introduced to identify oligometastatic prostate cancer patients. In this retrospective, exploratory study (...) , we report on the efficacy of PSMA-PET-guided local ablative radiotherapy (aRT) in 15 oligometastatic castration-resistant prostate cancer (CRPC) patients, selected from our prospective institutional database and treated between 2013 and 2016. After multidisciplinary discussion, aRT was delivered with two different schedules. Androgen deprivation therapy remained unchanged. Prostate-specific antigen (PSA) response and time to PSA progression were analysed. For comparison, individual time to PSA

2018 European Urology

212. Impact of staging <sup>68</sup>Ga-PSMA-11 PET scans on radiation treatment plans in patients with prostate cancer. (Abstract)

Impact of staging 68Ga-PSMA-11 PET scans on radiation treatment plans in patients with prostate cancer. To evaluate the impact of staging 68Ga-PSMA-11 PET imaging on radiotherapy (RT) dose and volumes in patients with prostate cancer.Forty-five patients (89% high or very high risk by NCCN criteria) who underwent 68Ga-PSMA-11 PET imaging prior to definitive treatment for prostate cancer between December 2015 and December 2016 were included. Locations of 68Ga-PSMA-11-avid lesions were (...) compared to Radiation Therapy Oncology Group consensus pelvic nodal volumes (clinical target volume [CTV]); coverage of lesions outside the consensus CTV was considered a major change, while dose-escalation to lesions within the consensus CTV was considered a minor change.All patients had 68Ga-PSMA-11 PET uptake in the prostate. Twenty-five patients (56%) had N1/M1a disease on 68Ga-PSMA-11 PET scan, of whom 21 (47%) were previously N0. Six patients (13%) had bone metastases on 68Ga-PSMA-11 PET scan

2018 Urology

213. TNM clinical staging of prostate cancer: Issues and solutions. Full Text available with Trip Pro

TNM clinical staging of prostate cancer: Issues and solutions. 30315677 2019 03 01 1464-410X 123 3 2019 Mar BJU international BJU Int. TNM clinical staging of prostate cancer: issues and solutions. 382-384 10.1111/bju.14589 Varma Murali M http://orcid.org/0000-0003-1385-2045 Department of Pathology, Cardiff and Vale University Heath Board, Cardiff, UK. Cochlin Dennis D Department of Radiology, Cardiff and Vale University Heath Board, Cardiff, UK. Delahunt Brett B Department of Pathology (...) , Wellington School of Medicine and Health Sciences, Wellington, New Zealand. Kynaston Howard H Department of Urology, Cardiff and Vale University Heath Board, Cardiff, UK. Rees John J Department of Radiology, Cardiff and Vale University Heath Board, Cardiff, UK. Rous Brian B Department of Pathology, National Cancer Registration and Analysis Service, Cambridge, UK. Narahari Krishna K Department of Urology, Cardiff and Vale University Heath Board, Cardiff, UK. eng Letter 2018 10 31 England BJU Int 100886721

2018 BJU international

214. PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. Full Text available with Trip Pro

PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. Primary staging of prostate cancer relies on modalities, which are limited. We evaluate simultaneous [68Ga]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method for primary tumor-node-metastasis staging compared with histology and its impact on therapeutic decisions.We investigated 122 patients with PSMA-PET/MRI prior to planned radical prostatectomy (RP). Primary endpoint was the accuracy of PSMA-PET (...) /MRI in tumor staging as compared with staging-relevant histology. In addition, a multidisciplinary team reassessed the initial therapeutic approach to evaluate its impact on the therapeutic management.PSMA-PET/MRI correctly identified prostate cancer in 119 of 122 patients (97.5%). Eighty-one patients were treated with RP and pelvic lymphadenectomy. The accuracy for T staging was 82.5% [95% confidence interval (CI), 73-90; P < 0.001], for T2 stage was 85% (95% CI, 71-94; P < 0.001), for T3a stage

2018 Clinical Cancer Research

215. Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging? (Abstract)

Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging? Node-positive nonmetastatic prostate cancer is currently prognosticated as stage IV, despite evidence that a proportion of this patient population can be cured. We provide evidence and request reconsideration of prognostic staging in the next edition of the American Joint Committee on Cancer staging manual.Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2018 European Urology

216. Generation of multiparametric MRI maps by using Gd-labelled- RBCs reveals phenotypes and stages of murine prostate cancer Full Text available with Trip Pro

Generation of multiparametric MRI maps by using Gd-labelled- RBCs reveals phenotypes and stages of murine prostate cancer Prostate Cancer (PCa) is the second most common and fifth cause of cancer-related mortality in males in Western Countries. The development of innovative tools for an early, more precise and noninvasive diagnosis is a medical need. Vascular volume (Vv) and hypoxia are two of the most important tumor hallmarks. Herein, they have been assessed in TRAMP mice by using MRI (...) weighted MRI and Amide Proton Transfer MRI have been herein applied to characterize PCa. The herein applied multiparametric MRI (mpMRI) analysis allows a detailed in vivo characterization of PCa, in which each histotype and cancer stage displays a specific MRI pattern. This provides an unprecedented opportunity to feature prostate tumor, making possible a non-invasive, precise and early diagnosis, which could direct treatments towards a more personalized medicine.

2018 Scientific reports

217. Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage Full Text available with Trip Pro

Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage Although several methods have been developed to predict the outcome of patients with prostate cancer, early diagnosis of individual patient remains challenging. The aim of the present study was to correlate tumor perfusion parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and clinical prognostic factors and further to explore (...) the diagnostic value of DCE-MRI parameters in early stage prostate cancer.Sixty-two newly diagnosed patients with histologically proven prostate adenocarcinoma were enrolled in our prospective study. Transrectal ultrasound-guided biopsy (12 cores, 6 on each lobe) was performed in each patient. Pathology was reviewed and graded according to the Gleason system. DCE-MRI was performed and analyzed using a two-compartmental model; quantitative parameters including volume transfer constant (Ktrans), reflux

2018 Contrast media & molecular imaging

218. Modulation in the microRNA repertoire is responsible for the stage-specific effects of Akt suppression on murine neuroendocrine prostate cancer Full Text available with Trip Pro

Affymetrix analysis to compare the expression profile of microRNAs in the mouse prostate tissues collected at the prostatic inter-epithelial neoplasia (PIN) stage from Transgenic adenocarcinoma of the mouse (TRAMP)/Akt1+/+ versus TRAMP/Akt1-/- mice, and at the advanced stage from TRAMP/Akt1+/+ mice treated with triciribine (Akt inhibitor) versus DMSO-treated control. Our analysis demonstrates that in the early stage, Akt1 in the TRAMP prostate tumors express a set of miRNAs responsible for regulating (...) Modulation in the microRNA repertoire is responsible for the stage-specific effects of Akt suppression on murine neuroendocrine prostate cancer Recent studies indicate a stage-specific, differential role for the oncogene Akt on various cancers. In prostate cancer (PCa), suppression of Akt activity in the advanced stages promoted transforming growth factor-β (TGFβ) pathway-mediated epithelial-to-mesenchymal transition (EMT) and metastasis to the lungs. In the current study, we performed

2018 Heliyon

219. Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer Full Text available with Trip Pro

Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer In patients with prostate cancer, the presence of lymph node (LN) metastases is a critical prognostic factor and is essential for treatment planning. Conventional cross-sectional imaging performs poorly for nodal staging as both computed tomography (CT) and magnetic resonance imaging (MRI) are mainly dependent on size and basic morphological criteria. Therefore, extended pelvic LN dissection (ePLND) remains the gold (...) emission tomography (PET) tracers. In this article, the current state of data supporting DWI in LN staging of patients with prostate cancer is discussed.

2018 Translational andrology and urology

220. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014 Full Text available with Trip Pro

Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014 Current literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence, in part, due to low study population coverage and wide age groupings. This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data.Data on prostate (...) cancer cases came from the 2004-2014 United States Cancer Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated annual percentage change (APC).We identified 2,137,054 incident prostate cancers diagnosed during 2004-2014, with an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence significantly decreased during 2004-2010

2018 Annals of Epidemiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>